Floatz logo

Nivolumab

Broad Solid Tumor

Bristol-Myers Squibbmonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Broad Solid Tumor cohort.

Asset / SponsorPhaseRating
Ipilimumab
Bristol-Myers Squibb
Phase 1/2CCC
Immunoglobulin G1 [247-alanine,248-glutamic acid,250-alanine,343-serine,344-serine,de-C-terminal-lysine], anti-(human T cell immunoreceptor with Ig and ITIM domains) (human monoclonal BMS-986207 ?1-chain), disulfide with human monoclonal BMS-986207 ?-chain, dimer
Bristol-Myers Squibb
Phase 1/2CCC

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →